• EZZ expands China growth strategy with JD Health Platform strategic cooperation framework
• JD Health operates one of China’s largest online healthcare ecosystems
• Framework will see EZZ tap into JD Health’s large user base, integrated supply chain and ecosystem

Special Report: EZZ Life Science Holdings has struck a strategic cooperation framework with JD Health, marking a further push into China’s rapidly expanding health and wellness market.

JD Health, a subsidiary of JD.com and listed on the Hong Kong Stock Exchange, operates one of China’s largest online healthcare ecosystems, spanning pharmaceuticals, supplements, medical services and digital health solutions.

The strategic cooperation framework will see EZZ Life Science Holdings (ASX: EZZ) distribute and promote its premium health supplement range via JD Health’s platform, tapping into its large user base, integrated supply chain and digital healthcare ecosystem.

EZZ and JD Health will collaborate across product launches, digital marketing campaigns and customer acquisition initiatives, while also working to optimise the end-to-end consumer experience.

The partnership builds on EZZ’s strategy to deepen its presence across leading Chinese e-commerce and digital health platforms, with a continued emphasis on premium positioning and product quality.

EZZ said it intends to leverage JD Health’s platform capabilities to support new product launches, broaden its customer reach and strengthen engagement with Chinese consumers.

Key initiatives under the framework include the rollout of core supplement products on JD Health, joint brand and marketing campaigns, targeted customer acquisition strategies and enhancements to logistics and service delivery.

The collaboration is expected to support EZZ’s broader objective of building a more diversified and resilient revenue base across multiple channels and geographies.

Strengthening presence in key market
EZZ has been enjoying strong momentum across key Asian markets, particularly China, where it has built a reputation for high-quality health and wellness innovation.

The company formulates, produces, markets and distributes health supplements under the EZZ brand throughout Asia, while investing in research and development alongside third-party partners to create products capable of securing strong market positions.

More than 65% of EZZ’s revenue is now derived from China, with the company establishing a significant presence and executing targeted digital marketing strategies across leading Chinese e-commerce platforms including Douyin, Kuaishou and Tmall.

CEO Mark Qin said JD Health was one of China’s leading digital healthcare platforms, and the partnership provided EZZ with an opportunity to further strengthen its presence in the key market.

“By combining JD Health’s platform capabilities with EZZ’s premium product offering, we are well positioned to expand our reach, enhance customer engagement and support future growth.

“Importantly, this collaboration aligns with our strategy of building a more diversified and sustainable business across multiple markets and channels.”

This article was developed in collaboration with EZZ Life Science Holdings, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.